GLENN D. STEELE JR. - Corporate Board Profile

WEIS MARKETS INC

Filing Date	Source Excerpt
2010-03-11	Glenn D. Steele Jr. Dr. Steele is President and Chief Executive Officer of Geisinger Health System. In this capacity, he serves as a member of the Geisinger Health System Foundation Board of Directors, ex-officio of all Standing Committees of the Board and Chairman of the subsidiary boards. Dr. Steele previously served as the Dean of the Biological Sciences Division of the Pritzker School of Medicine and as Vice President for Medical Affairs at the University of Chicago, as well as the Richard T. Crane Professor in the Department of Surgery.
2011-03-10	Glenn D. Steele Jr. Dr. Steele is President and Chief Executive Officer of Geisinger Health System. In this capacity, he serves as a member of the Geisinger Health System Foundation Board of Directors, ex-officio of all Standing Committees of the Board and Chairman of the subsidiary boards. Dr. Steele previously served as the Dean of the Biological Sciences Division of the Pritzker School of Medicine and as Vice President for Medical Affairs at the University of Chicago, as well as the Richard T. Crane Professor in the Department of Surgery. Dr. Steele serves on several boards including Bucknell Universitys Board of Trustees, Temple University School of Medicines Board of Visitors, the American Hospital Associations Board of Trustees, Premier, Inc. (Vice Chairman), Wellcare Health Plans, Inc., the Northeast Regional Cancer Institute and the Global Conference Institute. Dr. Steeles extensive background in the health care industry provides the Company with pharmaceutical and healthcare related expertise. Dr. Steeles experience as a director on other boards and his overall business and financial leadership perspective is a valuable asset to the Board. The 2010 Audit Committee was composed of Directors Shulman, Smith and Steele, with Dr. Steele ceasing to serve on the Audit Committee, effective July 9, 2010. The 2010 Compensation Committee was composed of Directors Shulman, Smith, Steele and Jonathan H. Weis. Director Compensation table shows total compensation of $40,000 for 2010.
2012-03-15	Dr. Steele27s extensive background in the health care industry provides the Company with pharmaceutical and healthcare related expertise. Dr. Steele27s experience as a director on other boards and his overall business and financial leadership perspective is a valuable asset to the Board. The Board has determined that Directors Silverman and Steele are independent within the meaning of the listing standards of the NYSE. The 2011 Audit Committee was composed of Directors Richard E. Shulman, Silverman, Smith and Steele. Upon the expiration of Mr. Shulman27s term as a director in April 2011, Dr. Steele joined the Audit Committee to provide for three independent directors. Mr. Shulman served as Chairman of the Audit Committee until his term as a director expired, at which point Mr. Smith became Chairman of the Audit Committee. The Audit Committee held four regular meetings and three special meetings during fiscal 2011. Upon the expiration of Mr. Smith27s term as a director in April 2012, the Audit Committee will be comprised of Directors Silverman and Steele. The Company expects to appoint another independent non-employee director to the Board to fill the seat vacated by Mr. Smith and such independent non-employee director will be appointed to the Audit Committee by the Company27s Board to provide for three independent directors. The 2011 Compensation Committee was composed of Directors Shulman, Silverman, Smith, Steele and Jonathan H. Weis. Upon the expiration of Mr. Shulman27s term as a director, Mr. Silverman joined the Compensation Committee. Mr. Weis served as Chairman of the Compensation Committee. Upon the expiration of Mr. Smith27s term as a director, the Compensation Committee will be comprised of Directors Silverman, Steele and Jonathan H. Weis. The Compensation Committee held two regular meetings during fiscal 2011.
2013-03-14	Dr. Steele27s extensive background in the health care industry provides the Company with pharmaceutical and healthcare related expertise. Dr. Steele27s experience as a director on other boards and his overall business and financial leadership perspective is a valuable asset to the Board. The 2012 Audit Committee was composed of Directors Steven C. Smith, Silverman, Steele and Lauth. Mr. Smith ceased to serve on the Audit Committee when his term as director expired in April 2012. The Compensation Committee was composed of Directors Smith, Silverman, Steele and Jonathan H. Weis. Mr. Smith ceased to serve on the Compensation Committee when his term as director expired in April 2012.
2014-03-13	Glenn D. Steele Jr. Dr. Steele has served as President and Chief Executive Officer of Geisinger Health System, an integrated health services organization in central and northeastern Pennsylvania nationally recognized for its innovative use of the electronic health record and the development and implementation of innovative care models, since 2001. Dr. Steele previously served as the Dean of the Biological Sciences Division and the Pritzker School of Medicine and as Vice President for Medical Affairs at the University of Chicago, as well as the Richard T. Crane Professor in the Department of Surgery. Dr. Steele serves on several boards including Bucknell University’s Board of Trustees, Cepheid and Wellcare Health Plans, Inc. Dr. Steele most recently served as Board Chairman for Premier Inc., former Trustee on the Temple University School of Medicine Board of Visitors and Harvard Medical Faculty Physicians Board at Beth Israel Deaconess Medical Center. Dr. Steele’s extensive background in the health care industry provides the Company with pharmaceutical and healthcare related expertise. Dr. Steele’s experience as a director on other boards and his overall business and financial leadership perspective is a valuable asset to the Board. The 2013 Audit Committee was comprised of Directors Silverman, Steele and Lauth. Mr. Silverman served as Chairman of the Audit Committee through April 25, 2013, at which point Mr. Lauth became Chairman of the Audit Committee. The Audit Committee held four regular meetings and four special meetings during fiscal 2013. The Board has determined that all Audit Committee members are financially literate under the listing standards of the NYSE. The Board also determined that all Audit Committee members were “audit committee financial experts” in fiscal 2013 and all Audit Committee members are “audit committee financial experts” in fiscal 2014, as defined in Item 401(h) of Regulation S-K, and all members of the Audit Committee are “independent” for purposes of Section 10A(m)(3) of the Securities Exchange Act of 1934 and the listing standards of the NYSE. The 2013 Compensation Committee was comprised of Directors Lauth, Silverman, Steele and Jonathan H. Weis. Mr. Weis served as Chairman of the Compensation Committee through April 25, 2013, at which point he ceased to serve on the Compensation Committee and Mr. Lauth was appointed to the Compensation Committee. Mr. Silverman served as Chairman of the Compensation Committee for the remainder of the year. Directors who are not officers of the Company or any of its subsidiaries receive an annual retainer of $40,000 paid in quarterly installments during the year. The Chairman of the Audit Committee receives an additional $6,000 annual retainer fee paid in quarterly installments during the year. In addition, each non-management independent director is entitled to reimbursement for out-of-pocket expenses to attend meetings. There is no additional remuneration for services rendered by directors serving on committees or for participation in the non-management independent director meetings.
2015-03-13	The 2014 Audit Committee was comprised of Directors Lauth, Silverman and Steele. Mr. Lauth served as Chairman of the Audit Committee. The 2014 Compensation Committee was comprised of Directors Lauth, Silverman and Steele. Mr. Silverman served as Chairman of the Compensation Committee. DIRECTOR COMPENSATION The following table shows the compensation earned by the Company’s non-management independent directors for services during fiscal 2014. Glenn D. Steele Jr. 77,500 77,500